Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis to buy Chattem for $1.9bn

Sanofi-aventis is to acquire US consumer healthcare company Chattem in a deal valued at around $1.9bn

Sanofi-aventis is to acquire US consumer healthcare company Chattem in a deal valued at around $1.9bn – equal to £93.50 a share in cash, which is 34 per cent above Chattem's closing price on December 18.

The purchase will create the world's fifth-largest consumer health company by revenue and is in line with CEO Chris Viehbacher's strategy to broaden sanofi-aventis' business.

Viehbacher said the acquisition "will be a significant milestone in sanofi-aventis' transformation strategy" to convert prescription medicines to over-the-counter (OTC) products. He added "we've never had a consumer healthcare presence in the US, Chattem is the ideal entry for us into this market."

The French drugmaker plans to convert Allegra (fexofenadine) to an OTC product. The antihistamine, which has faced generic competition since 2005, saw branded sales of €688m ($985m) last year.

Viehbacher explained "we've had significant interest from the major actors in the OTC world to switch Allegra. There's a huge appetite for a switch like this."

The companies indicated that the transaction will close in the first quarter of 2010.

22nd December 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics